Amprion and Modality.AI Break New Ground in Multimodal Assessment for Neurodegenerative Disease
Amprion, a global leader in the diagnosis of neurodegenerative disorders through seed amplification testing, and Modality.AI, a leader in AI-enabled multimodal clinical assessments, announced a collaboration to explore how molecular biomarkers and objective digital assessments can be integrated to improve the characterization of central nervous system (CNS) disorders.
The collaboration combines Amprion’s expertise in detecting disease-specific misfolded proteins with Modality.AI’s browser-based Tina platform, which uses structured audiovisual conversations to generate objective measures of speech, language, facial expression, cognition, and behavior. By integrating molecular biomarkers with AI-enabled digital assessments, the companies aim to improve patient characterization and disease monitoring, support clinical research, and generate richer multimodal datasets for neurodegenerative disease studies.
Neurodegenerative diseases aren’t defined by a single signal, and they shouldn’t be assessed that way,” said Russ Lebovitz, MD, PhD, CEO and Co-Founder of Amprion. “At Amprion, our work has always been rooted in revealing the underlying biology of disease. By combining molecular biomarkers with scalable digital assessments, we have an opportunity to connect biological changes with how disease presents and progresses in patients. That more complete picture can support better research, more informed clinical decision-making, and ultimately better patient outcomes.
CNS disorders are complex, heterogeneous diseases that cannot be fully understood through any single measurement,” said David Suendermann-Oeft, PhD, Founder and CEO of Modality.AI. “Integrating biological insights with objective digital measures has the potential to provide a more comprehensive understanding of disease development and progression.
Initially, the collaboration will focus on applications in clinical research, observational cohorts, and biopharma-sponsored studies, where paired molecular and digital assessments may improve patient stratification, reduce biological heterogeneity, monitor disease progression, and generate evidence to support future therapeutic development.
Early areas of focus are expected to include Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy (MSA), amyotrophic lateral sclerosis (ALS), and related neurodegenerative disorders.
The collaboration reflects the growing adoption of multimodal approaches in neuroscience research. As biomarker science and digital health technologies continue to advance, integrating biological and functional data may enable a more complete understanding of disease progression while supporting the development of precision medicine for neurodegenerative disorders.
Amprion will showcase its latest scientific advances at the Alzheimer’s Association International Conference (AAIC), taking place July 12–15, 2026, at ExCeL London in the United Kingdom. Attendees can meet with the Amprion team at booth #200.
About SAAmplify-ɑSYN (formerly SYNTap®)
SAAmplify-ɑSYN is Amprion’s first-in-class qualitative Laboratory Developed Test (LDT) and the only commercially available seed amplification assay designed to aid in the diagnosis of synucleinopathies, including Parkinson’s disease, dementia with Lewy bodies, and Alzheimer’s disease with Lewy body co-pathology. In 2019, the U.S. Food and Drug Administration granted the test Breakthrough Device Designation as an aid in the diagnosis of Parkinson’s disease. The test became commercially available in the United States in 2021.
About Amprion
Amprion is a global leader advancing the diagnosis of neurodegenerative disorders through seed amplification testing. The company’s intellectual property in seed amplification assay (SAA) technology supports applications spanning research, drug development, and clinical commercialization. Through its SAAmplify-ɑSYN test and partnerships with biopharmaceutical companies, Amprion is helping accelerate precision medicine by enabling earlier, more accurate detection of underlying neurodegenerative pathologies and supporting the development of targeted therapeutics.
About Modality.AI
Modality.AI provides technology for the objective assessment of central nervous system conditions through automated speech, language, facial, cognitive, and behavioral analytics elicited by Tina, a virtual clinical guide. Modality’s browser-based platform is designed for use in decentralized and site-based clinical studies, enabling standardized, scalable, and patient-centered assessments across neurological and psychiatric conditions.
Source link: https://www.businesswire.com/
